Jesse co-chairs Harris Sliwoski’s Dispute Resolution / Litigation practice group. He has an extensive domestic and international litigation background and has represented clients from a wide range of industries in high stakes disputes. Jesse represents numerous clients in the cannabis industry and he regularly writes on litigation issues involving hemp and CBD. In every dispute, it is Jesse’s goal to find the best and most cost-effective solution for his clients. His analytical mind, excellent writing skills, and steady presence allow him to find unique solutions to complicated domestic and international disputes.
The use of psilocybin (magic mushrooms) for therapeutic purposes gains traction Last month, the NBA and its players association reached a tentative deal that the league would no longer test players for marijuana. Indeed, the NBA is lifting its ban on marijuana in the new collective bargaining agreement. Meanwhile, the NFL and its players agreed
Among the emerging medical uses for MDMA and psilocybin is their relative dimethyltryptamine (DMT). Although a Schedule I drug in the United States, DMT increasingly is the subject of study for its potential efficacy in treating a wide array of mental-health conditions including depression, anxiety, and PTSD. Much of this research is occurring outside of
As the Oregon Health Authority moves forward with creating a program for the legal consumption of psilocybin following the enactment of Measure 109, other efforts to normalize the medical use of psilocybin continue. This week the Ninth Circuit ruled on a case concerning whether a physician may administer psilocybin without incurring liability under the Controlled
DMT, or N, N-dimethyltryptamine is a powerful psychedelic. DMT, like its sister psychedelics (LSD, MDMA, psilocybin … and even marijuana), is a Schedule I controlled substance. So according to the DEA, its abuse potential is high and it has no medical use. Also, according to the DEA, “the history of human experience probably goes back
Last Friday, May 22, petitioners submitted to the Oregon Secretary of State a ballot initiative (IP 34) seeking to permit the use of psilocybin for therapeutic use under a licensing and regulatory framework administered by the Oregon Health Authority (“OHA”). The submission was quite a feat, especially given the challenges presented by COVID-19 during the
Earlier this year we wrote about the movement to decriminalize psilocybin – noting its success in Denver, Oakland, and Santa Cruz – and that nearly 100 other cities are looking at decriminalizing psychedelics. (The Psilocybin Movement is Like the Cannabis Movement (Except When It’s Not)). That article posited that psilocybin would move along two tracks
A few weeks ago, we wrote about the proliferation of ketamine clinics in the United States and the logistics and legalities of operating a ketamine infusion clinic. As we explained, the only FDA approved use of ketamine is for the induction and maintenance of anesthesia, though it also used for off-label infusions in the management
